ERBB2 and breast carcinoma: Moreover, androgen-receptor (AR) positivity characterizes 10–15% of TNBC [3,4], and is often associated with clinicopathological features resembling HR+/HER2- breast cancer (BC), with frequent association with older age and late relapse [55,56].